All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MDS Alliance

The MDS Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Which subgroups of patients benefit most from a Ven+Aza combination?

During the 2021 ASCO Annual Meeting, the MDS Hub spoke with Pierre Fenaux, Hôpital Saint-Louis, Paris, FR. We asked, Which subgroups of patients benefit most from a Venetoclax+Azacitidine (Ven+Aza) combination?

Which subgroups of patients benefit most from a Ven+Aza combination?

Fenaux explains the current use for Ven+Aza before outlining early efficacy data from trials investigating this combination for high-risk MDS, highlighting the effect on earlier response rates and preventing later myelosuppression. He then suggests further stratification of this subgroup, including karyotype and transplant eligibility. Finally, he proposes the possibility for new combination therapies to improve survival in MDS.

Share: